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ABSTRACT 
IS DEXAMETHASONE 4MG A MORE EFFECTIVE ANTI-EMETIC THAN 
DEXAMETHASONE 8MG FOR THE PREVENTION OF EARLY 
POST-OPERATIVE NAUSEA AND VOMITING IN WOMEN 
UNDERGOING LAPAROSCOPIC GYNECOLOGICAL SURGERY? 
by Steven Blake Doyle 
December 2015 
Postoperative nausea and vomiting (PONV) is a common problem in the surgical 
setting. It affects as much as 20 to 80 percent of patients undergoing surgery (D'souza, 
Swami, & Bhagwat, 2011). PONV can lead to increased patient costs and recovery time 
by causing the patient to stay in the healthcare facility for a longer period of time. A 
retrospective cohort study was completed to examine whether or not there was a 
significant difference between patients who received 4mg and 8mg of dexamethasone in 
the incidence of PONV. All patients studied received ondansetron intraoperatively as 
their primary anti-emetic. English-speaking patients who met the following inclusion 
criteria were included in the retrospective chart review: those who are female, those who 
have undergone laparoscopic gynecological surgery and received dexamethasone, those 
who are non-smokers, and those who are aged 18-60 with an American Society of 
Anesthesiologists (ASA) score of II or less. Patients that met the following exclusion 
criteria were not counted towards the chart review: those who are an ASA III or above, 
those who did not follow the recommended fasting time prior to surgery, those with a 
history of motion sickness, those with a history of PONV, those who are taking routine  
anti-emetics, those whose are deaf, those who are blind, those who are smokers, and 
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those outside the age range for 18-60 years. Statistical analysis using a Chi-Square test 
was used to evaluate whether the patients receiving 4mg of dexamethasone experienced 
more PONV that those who received 8mg.  
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CHAPTER I 
INTRODUCTION 
Statement of the Problem 
 Post-operative nausea and vomiting (PONV) is a common problem in the 
surgical settings. It affects as much as 20 to 80 percent of patients undergoing surgery 
(D'souza, Swami, & Bhagwat, 2011). Sustained vomiting is one of the most frequent 
causes of unexpected hospital admission of patients from ambulatory surgery centers 
(Yao, Fontes, & Malhotra, 2012). PONV contributes to additional problems such as 
anxiety, patient dissatisfaction, dehydration, muscular fatigue, and delayed recovery.  
PONV has many different triggers. History of PONV, female gender, 
laparoscopic procedures, opioids, being a non-smoker, and duration of surgery have all 
been linked to increased incidence of PONV (Miller & Pardo, 2011).  The chemoreceptor 
trigger zone (CTZ) located in the brainstem is believed to be responsible for nausea and 
vomiting. The CTZ contains opioid, serotonin, histamine, dopamine, and muscarinic 
acetylcholine receptors, which when triggered, cause nausea and vomiting (Barash et al., 
2013). The CTZ, vagal nerve, and vestibular organs send signals to the vomiting center in 
the medulla leading to PONV (Barash et al., 2013). A multimodal drug therapy approach 
can be effective in blocking stimulation of the receptors of the CTZ, thus preventing 
PONV.   
There are many different approaches to preventing PONV. One particular method 
that is popular is treating PONV prophylactically with the anti-emetic drug ondansetron. 
It has been reported that many patients have greater fear of PONV than they do of 
experience pain as a result of their procedure (Sweeny, 2003). If left untreated, the 
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incidence PONV varies greatly amongst populations being studied, with an occurrence 
rate of 20-30% in the general surgical population and as high as 70-80% in high-risk 
surgical populations (Jee, Yoon, & Jang, 2010).  
There are many different factors that can make a patient more or less susceptible 
to experiencing PONV. Many of these risk factors can be identified by a thorough pre-
anesthetic evaluation with a complete history and physical. One factor which can be 
assessed is being obese. Obese patients have a higher incidence of PONV than non-obese 
patients (Sweeny, 2003). Some explanation for this could be that anesthetic medications 
could be deposited in adipose tissues and be released while the patient is in the recovery 
room. Other problems with having a larger body size can be that larger people have 
increased resting stomach volumes. The more volume one has in their stomach, the more 
likely it is for that person to have an incidence of vomiting. 
Gender plays a role in determining the risk factor of PONV. Women are four 
times more likely to have PONV than men (Sweeny, 2003). This is even more likely to 
occur in younger women due to the fact that the incidence of PONV also decreases with 
age (Sweeny, 2003). These are major reasons why the proposed study is focusing on 
women undergoing general anesthesia as the population of interest in regards to PONV 
since they are more likely to experience it than men. 
The type of surgical procedure can also have a major influence of PONV. 
Gynecological and abdominal surgery patients are at a much greater risk of PONV than 
patients undergoing other surgery types such as bone fracture repair. Some procedures 
that are commonly associated with PONV are strabismus surgery, ear surgery, 
laparoscopy, orchiopexy, ovum retrieval tonsillectomy, and breast surgery (Butterworth, 
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Mackey, & Wasnick, 2013). Considering which type of surgical procedure the patient is 
undergoing can aid the anesthetist in making an assessment of how much the patient is at 
risk for PONV.  
The type of anesthetic used and the duration of the procedure also can play a role 
in determining the risks of PONV. The longer the procedure, the greater the chance for 
PONV. General anesthesia has a greater incidence of PONV. Nitrous oxide has also been 
linked to increased incidence of PONV, as well as the use of opioids for pain 
management (Sweeny, 2003).  
There are several things, such as age, gender, duration of surgery, and body 
weight that cannot be controlled by the anesthetist to prevent the incidence of PONV. 
However, there are some factors that can be controlled such as fluid replacement and 
which anesthetic agents are used throughout the procedure (Sweeny, 2003) . It is 
important to note how much fluid the anesthetist is giving the patient during the pre-
operative, intraoperative, and postoperative state. Although there have been numerous 
studies seeking to define fluid strategy, anesthetists giving liberal, standard, or restrictive 
amounts of fluids have not been able to consistently improve postoperative outcomes 
(Butterworth, Mackey, & Wasnick, 2013). As always, when considering fluid 
resuscitation, the anesthetist should consider the patient’s comorbidities such as 
cardiovascular history when selecting a fluid resuscitation strategy.  
 The anti-emetic drug ondansetron is a popular drug of choice for most anesthetists 
in preventing and treating PONV. Ondansetron selectively block serotonin 5-HT 
receptors with minimal to no effect on dopamine receptors (Butterworth, Mackey, & 
Wasnick, 2013). 5-HT receptors appear to play an important role in the initiation of the 
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vomiting reflex. These receptors are located outside of the blood-brain barrier, which are 
activated by substances such as anesthetics and opioids (Butterworth, Mackey, & 
Wasnick, 2013). Thus the use of ondansetron is very effective in offsetting the emetic 
effects of most drugs given during anesthesia. Ondansetron is metabolized in the liver via 
cytochrome P-450 enzymes, and it is important to consider the dosage in patients who 
have any signs of liver failure as to avoid toxicity (Butterworth, Mackey, & Wasnick, 
2013). Ondansetron in a dosage of 4mg has been seen to be just as effective as 8mg when 
it is administered in the post-anesthesia care unit for treatment of nausea and vomiting 
(Nagelhout & Plaus, 2014). 
Dexamethasone is a glucocorticoid steroid drug that has been found to be an 
effective treatment in reducing the incidence of PONV, given alone or in combination 
with other anti-emetic drugs (Nagelhout & Plaus, 2014).  Dexamethasone should be 
given immediately after induction instead of at the end of surgery, and the mechanism of 
action in preventing PONV is unknown (Butterworth, Mackey, & Wasnick, 2013). The 
beneficial effects of dexamethasone in preventing PONV could be secondary to its long 
duration of action, which can last up to 24 hours (Nagelhout & Plaus, 2014). 
Dexamethasone in doses as small as 4mg has been shown to be as effective as 
ondansetron in reducing the incidence of PONV (Butterworth, Mackey, & Wasnick, 
2013). Dexamethasone at a dosage of 4mg and 8mg have been shown to prevent PONV 
(D'souza, Swami, & Bhagwat, 2011). Dexamethasone is commonly supplied in 4mg/1ml 
vials.  
As with ondansetron, dexamethasone is also metabolized in the liver via 
cytochrome P-450 enzymes. Adverse effects of single dose of dexamethasone have not 
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been reported, however, patients who are sensitive to steroid administration, such as 
patients with diabetes, should be considered carefully as steroids have a tendency to 
increase blood glucose levels (Nagelhout & Plaus, 2014). Dexamethasone also acts in the 
inhibition of prostaglandin synthesis thus preventing swelling, which could prove 
especially useful to surgeons and anesthetists during neck and airway procedures 
(Nagelhout & Plaus, 2014).  
Conceptual and Theoretical Framework 
 The use of prescriptive theory, including its basic tenets, assumptions, and theory 
parts, will serve as a theoretical framework for the capstone project involving the use of 
dexamethasone intravenously for the prevention of post-operative nausea and vomiting. 
Future practice implications of prescriptive theory are abundant, as most experiments 
measuring interventions can be applied to prescriptive theory. 
 Prescriptive theory is a subclass of a group of theories known as middle range 
theories. When theorists produced middle-range theories, they chose conceptual models 
that align with his or her own expectations of the world. Many middle range theories are 
created from the same conceptual model (Butts & Rich, 2011).  According Butts and 
Rich, “Many middle-range theories are needed to deal with all of the phenomena 
encompassed by any one conceptual model because each theory deals with only a limited 
aspect of the total reality encompassed by a conceptual model” (p.36). Middle-ranged 
theories can further be broken down into subclasses. McKenna and Slevin outlined four 
types of scientific categories, descriptive, explanatory, prescriptive, and finally 
prescriptive theory (Butts & Rich, 2011). Prescriptive theory prescribes evidence and 
uses knowledge utilization that looks beyond the predictive cause-and-effect 
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relationships. Prescriptive theory builds on other the other subclasses of middle-range 
theory that consists of descriptive, explanatory, and predictive theory (Butts & Rich, 
2011). The adaptation of prescriptive theory could aid clinicians by providing evidence of 
cause-and-effect relationships between interventions, such as intravenous administration 
of dexamethasone, to predict outcomes like the prevention of PONV. In other words, 
prescriptive theory addresses aspects of therapeutic interventions. This capstone project, 
as previously described, will be addressing a pharmacological intervention in the 
prevention of PONV. The administration of dexamethasone to prevent PONV uses 
prescriptive theory by exploring cause-and-effect relationships, and investigating whether 
or not the intervention of administering dexamethasone intravenously is effective in 
preventing PONV. Evidence of the effectiveness or ineffectiveness of these interventions 
will be noted in order to influence current practice.  
Review of Literature 
Included in this section is a narrative review of literature concerning the use of 
dexamethasone in the prevention of PONV within various populations. The online 
database CINAHL and PubMed, were used to search for articles related to the clinical 
question at hand. The word “dexamethasone” was entered into line one, the words 
“postoperative nausea and vomiting” were entered into line two, and the word “women” 
was entered into line three. A total of 91 articles were found from CINAHL and 71 
articles from PubMed. Ten articles were used exclusively for the literature review that 
exclusively included the population of women aged 18 or older undergoing general 
anesthesia. 
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Gynecological surgery is considered a high risk factor for PONV (D'souza, 
Swami, & Bhagwat, 2011). A quantitative study by D’souza, Swami, and Bhagwat 
(2011) compared the use of intravenous dexamethasone and ondansetron for the 
prevention of PONV in young women undergoing laparoscopic gynecological surgery. 
Ninety-three women were randomly divided into 3 groups. One group received 4mg 
dexamethasone, another group 8 mg dexamethasone, and the final group received 4 mg 
of ondansetron. A PONV score was used as an assessment tool during the first 24 hours 
after surgery. 
The incidence of PONV during the 24 hour postoperative period was highest 
amongst the group that received 4 mg ondansetron within the first 3 hours 
postoperatively. In the dexamethasone 4 mg groups, the request for rescue antiemetic 
drugs was significantly lower than in the dexamethasone 8mg group and the ondansetron 
4mg group. Based on this study, it can be suggested that dexamethasone is an efficient 
cost effective drug for the prophylaxis of PONV, and the dexamethasone at a dosage of 
4mg was most effective amongst this population. 
Laparoscopic surgeries are the second most common cause of PONV (Maddali, 
Fahr, Fahr, & Zarrough, 2003) A comparison of dexamethasone with ondansetron against 
metoclopramide and dexamethasone for the prevention of PONV amongst female 
patients undergoing laparoscopic diagnostic gynecological surgery was examined by 
Maddali, Mathew, Fahr, and Zarroug (2003). Their research was conducted in the form of 
a perspective, randomized, double-blind study. One-hundred twenty women were given 
either saline (group 1), 8mg of dexamethasone with 10mg of metoclopramide (group 2), 
or 8mg dexamethasone with 4mg of ondansetron (group 3). There were no significant 
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differences amongst the group’s mean age, mean weight, duration of procedure, or 
duration of stay in the post anesthesia care unit (PACU). The patients were assessed for 
PONV every hour for 6 hours, then every 2 hours for 6 hours, and finally every 4 hours 
for the final 12 hours.  
Between the three groups, the results of the study were most favorable for the 
patients in group 3. The patients in group 1 suffered the highest incidence of nausea at 
45%, followed by group 2 at 40%, and group 1 at 17.5%. Interestingly enough, patients in 
group 1 did not suffer from vomiting, while 35% of group 2 and 10% of group 1 had 
incidence of vomiting. The researchers concluded that the use of dexamethasone with 
ondansetron as an efficient, cost-effective, and easily available way to prevent PONV 
than the use of dexamethasone with metoclopramide (Maddali, Fahr, Fahr, & Zarrough, 
2003). 
 The use of dexamethasone vs ketorolac for the prevention of PONV in women 
undergoing laparoscopic gynecologic surgeries was examined in a by Rimaitis, Svitojute, 
and Macas (2010). The researchers compared 153 women with American Society of 
Anesthesiologists (ASA) physical status score of I-II undergoing laparoscopic 
gynecological procedures. The women were divided into 3 random groups, a 
dexamethasone group, a ketorolac group, and a control group. The dosage of 
dexamethasone given was 4mg, while the ketorolac group received 30mg of ketorolac, 
and the control group received no medication at all. There were no significant 
demographic differences found within the population. Thirty-seven of the patients 
registered had a history of migraines. Fifty-nine and one-half percent of these patients 
suffered from PONV, while only 12.9% of patients without a history of migraine 
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headaches reported PONV. Of the groups examined, the dexamethasone group had 
13.8% of patients reporting PONV, while the ketorolac group had 37.3% of patients 
report PONV, and the control group suffered a rate of 58.9% of patients reporting PONV. 
The researchers concluded that history of migraine headache is an independent risk factor 
for PONV, 4 mg of dexamethasone during induction of anesthesia showed a significant 
difference in the reduction of PONV, and that the use of ketorolac during induction 
reduced the risk of PONV. 
It is well known that ondansetron is an effective anti-emetic drug. Yuksek, Alici, 
Erdem, and Cesur (2003) sought to compare ondansetron vs dexamethasone for the 
prevention of PONV in women undergoing laparoscopic gynecological surgery. The 
study consisted of women aged 19-62 years old undergoing general anesthesia for 
laparoscopic gynecological surgery. Patients with BMI > 35, history of gastric reflux 
were excluded. All patients completed the study.  
The 60 participants were randomly divided into 3 equal groups, one receiving 
4mg ondansetron, the other 8mg dexamethasone, and the last given saline. There was a 
significant difference seen between the groups during the first 3 hours after surgery. 
Ondansetron was found to be significantly more effective than dexamethasone and saline. 
Dexamethasone did not prevent PONV nor did saline within the first 3 hours. In fact, 
there were no significant differences found between the two. Based on this study, one 
could suggest that dexamethasone was ineffective in preventing early PONV, and 
ondansetron is the better choice to prevent PONV within the first 3 hours after surgery.  
Laparoscopic cholecystectomy is a very common laparoscopic abdominal 
procedure. While many studies have focused on the use of dexamethasone in 
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laparoscopic gynecological procedures, Choi, Jo, J. Lee, W. Lee, and Shim (2012) sought 
to compare the use of dexamethasone 8mg, ramosetron 0.3 mg, and dexamethasone 8mg 
combined with ramosetron 0.3mg in women undergoing laparoscopic cholecystectomy. 
The researchers randomly assigned 120 women into 3 groups, each receiving one of the 
mentioned drug regimens. The participants’ ages ranged from 21 to 64 years old, and had 
an ASA status of I-II. The researchers concluded that the combination of both 
dexamethasone and ramosetron was most effective in prevention of PONV, with 93% of 
participants showing complete response, followed by ramosetron at 78% and 
dexamethasone at 70%. 
Breast surgery under general anesthesia has been linked to an increased incidence 
of PONV. It is estimated that 60- 80% of patients having a mastectomy procedure with 
axillary dissection experience PONV (Fujii, 2006). Dr. Yoshitaka Fujii (2006) reviewed 
the use of dexamethasone as well as other traditional, non-traditional, and non-
pharmacological preventative measures for PONV for women undergoing mastectomy 
procedures. Fujii concluded that dexamethasone is effective for the prevention of PONV 
for patients undergoing a mastectomy, especially during the first 24 hours, and that 
dexamethasone is particularly effective when given in addition to other anti-emetics.  
Fujii later used the knowledge gained from the review to collaborate with Dr. 
Masahiro Nakayama (2007) to conduct a double-blind placebo-controlled trial to 
determine the effectiveness of dexamethasone for the prevention of PONV and the 
reduction of analgesic requirement in patients undergoing a mastectomy. Ninety women 
aged 40-66 with no history of gastrointestinal disease, history of PONV, or motion 
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sickness were randomly divided into three groups, one receiving 4mg dexamethasone, 
another 8mg of dexamethasone, and the last a placebo.  
Within 24 hours after the procedure, 33% of the dexamethasone 4mg patients 
experienced PONV, followed by 27% in the dexamethasone 8mg group, and 67% in the 
placebo group. The use of indomethacin as a pain reliever was requested by 83% of the 
placebo group, 70% of those who received 4mg dexamethasone, and 45% of the 
participants who received 8mg dexamethasone. The researchers suggested that 
dexamethasone at a dosage of 8mg was most effective in decreasing the incidence of 
PONV and pain in women undergoing general anesthesia for mastectomy. 
Motion sickness has been shown to cause an increased risk for PONV in the 
patient undergoing general anesthesia (Lee, Lai, Lin, Huang, & Lin, 2002). Lee et 
al.(2002) completed a double-blind, placebo-controlled study in which 168 female 
patients, half of which had a history of motion sickness, undertaking laparoscopic 
gynecological surgery were randomly divided into 2 groups and given 8mg of 
dexamethasone or saline immediately before induction of anesthesia.  
The results of the study yielded complete response to dexamethasone in 80.5% of 
patients with history of motion sickness and 37.5% of patients with history of motion 
sickness who received saline. In contrast, a complete response to dexamethasone was 
found in 83.3% of patients without history of motion sickness and 53.7% of those 
receiving saline. Calculation of efficacy within the subgroups showed dexamethasone 
was 45.3% more effective in patients with a positive history of motion sickness. In 
conclusion, Lee et al. found that dexamethasone is effective in both groups of patients 
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and that there were more favorable outcomes amongst patients who received 
dexamethasone with a history of motion sickness. 
Surgery type and population are not the only risk factors for PONV, the use of 
narcotic drugs in the perioperative period can increase the risk of PONV. A quantitative 
study by Young, Yoon, and Jang (2010) compared the use of ondansetron with 
dexamethasone vs metoclopramide with dexamethasone in patients undergoing 
gynecologic procedures who were also receiving fentanyl intravenous-patient controlled 
analgesia. A total of 100 patients were randomly divided into two groups. One group 
received 5mg dexamethasone after induction, and then was given 4 mg ondansetron at the 
end of the procedure, while the other group was given 5 mg of dexamethasone after 
induction with 20 mg metoclopramide at the end of the procedure. 
The results of the study found no significant differences between the two 
treatment modalities. The incidence of PONV was 44% in the group that received 
ondansetron and dexamethasone, and 38% in the group that received metoclopramide and 
dexamethasone. Both treatment modalities appeared to be effective in the prevention of 
PONV. 
The practitioner controls when to give medication. Correct timing of 
administration of medication is essential to achieving the desired effects. Wang, Ho, 
Tzeng, and Tang (2000) sought to determine optimal timing of the administration of 
dexamethasone for the prevention of PONV. 120 ASA I-II women ages 35-45 scheduled 
for total abdominal hysterectomy participated in a randomized, double-blind, placebo-
controlled study. Those with a positive history of gastrointestinal disease or prior use of 
antiemetics in the last 48 hours were excluded. The patients were randomly divided into 3 
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groups. Group 1 was given 10mg of dexamethasone prior to induction of anesthesia, 
group 2 received 10 mg dexamethasone after tracheal extubation, and group 3 only 
received saline. Within 2 hours post-operatively, only 8% of patients in group 1 needed 
rescue anti-emetics, followed by 30% of group 2 and 35% of group 3. Incidence of 
PONV during the first two hours post-operatively was present in 15% of group 1, 45% of 
group 2, and 53% of group 3. During hours 2-24 PONV was reported in 25% of group 1, 
28% of group 2, and 55% of group 3.  Based on these results, it is clear to see that 
dexamethasone should be given immediately before induction of anesthesia to achieve 
maximum efficacy in the prevention of PONV. 
In conclusion, numerous studies have indicated that dexamethasone is an efficient 
drug for the prevention of PONV in women undergoing general anesthesia. 
Dexamethasone at dosages of 4 and 8mg have both been shown to be effective, and 
giving dexamethasone as an adjunct to ondansetron or other traditional antiemetics shows 
favorable results. Evidence supports that dexamethasone is effective at preventing PONV 
in high risk patients with history of motion sickness. It is most beneficial to give 
dexamethasone at the induction of anesthesia, rather than at the end of surgery. None of 
the studies reviewed reported any incidence unwanted side effects. 
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CHAPTER II 
METHODOLOGY 
Target Outcome 
 The desired outcome of this capstone project is to determine whether or not there 
is a significant difference between the dosages of dexamethasone in regards to the 
prevention of PONV by completing a retrospective chart review. The knowledge gained 
could help anesthesia providers determine the most effective dosage of dexamethasone 
for their patients, which could in turn lead to cost savings by reducing the time spent in 
the PACU, and result in greater patient satisfaction through the reduction of PONV. If no 
significant difference is found, one could suggest that 4mg be administered instead of 
8mg in order to use less medication. 
Population 
Fifty patient charts that met the inclusion criteria were selected from patients that 
had laparoscopic gynecological surgery at a level 2 regional trauma center in the 
Southeastern United States. Each patient selected received ondansetron during the 
intraoperative period. English speaking patients who meet the following inclusion criteria 
were included in the retrospective chart review: those who are female, those who have 
underwent laparoscopic gynecological surgery and received dexamethasone, those who 
are non-smokers, and those who are aged 18-60 with an ASA of II or less. Patients that 
met the following exclusion criteria were not counted towards the chart review: those 
who are an ASA III or above, those who did not follow the recommended fasting time 
prior to surgery, those with a history of motion sickness, those with a history of PONV, 
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those who are taking routine anti-emetics, those whose are deaf, those who are blind, 
those who are smokers, and those outside the age range for 18-60 years. 
Barriers 
Clinical limitations to the accuracy of this retrospective chart review could 
include that some patients are simply more prone to PONV than others. The use of a 
retrospective chart study does not allow the researchers to give direct interventions, or 
finely control the amount of drugs and intravenous fluids given throughout the 
administration of anesthesia. Duration of surgical procedures can also vary, even if the 
surgeon is performing the same procedure on two different patients. As mentioned 
earlier, the longer the duration of surgery, the higher risk the patient is for PONV. There 
was difficulty finding an adequate number of patients that had received 4mg 
dexamethasone compared to 8mg. Eight mg dexamethasone was used by substantially 
more providers at the host site. A larger sample could have been obtained had there been 
a greater number of patients who received 4mg of dexamethasone. 
Setting 
A regional hospital in the Southeastern United States will serve as the setting for 
the retrospective chart review.  The hospital provides a large variety of surgical services 
for its surrounding community. There are many surgeons who routinely perform 
laparoscopic gynecological surgery within the setting. The hospital uses Electronic 
Patient Integrated Care (EPIC), which is an electronic health record used to store patient 
records. The use of EPIC was an additional bonus as it provided quick access to 
numerous medical records allowing the researcher to efficiently collect the sample. 
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Research Approaches 
 A retrospective chart review was completed in order to compare the outcomes of 
the two medications. A retrospective review involves the researcher looking at a group of 
patients who did or did not experience an event such as PONV. In the case of the study, 
the incidence of PONV was examined among 2 different groups of patients, one who 
received 4mg dexamethasone, and the other who received 8mg. A retrospective review 
prevents the researcher from making direct interactions to the patients being studied. This 
approach is deemed safe and appropriate as it allows anesthesia providers to care for their 
patients in the way they prefer, and does not directly influence patient care. Data was 
collected using the data collection form attached at the end of this paper. All data was de-
identified to protect patients’ protected private information. Statistical Package for the 
Social Sciences (SPSS) was used to make a statistical analysis which compared the data 
by using a chi-square test to determine whether or not there is a significant difference 
between the two dosages of medications in regards to early PONV. 
Sampling 
After given approval by the Institutional Review Board (IRB) at The University 
of Southern Mississippi and the capstone setting, a retrospective chart review was 
completed in order to collect data. Patients’ charts were searched using EPIC software. 
Patient sensitive information was not recorded. The patient summary page on EPIC was 
first used to see if the patient met the inclusion criteria. This page gives general 
demographic information on the patient, and gives a snapshot of their overall health such 
as co-morbidities, age, history of PONV or motion sickness, smoking status, and ASA 
score as given by the anesthesia provider that interviewed them prior to their procedure. 
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Once that patient was deemed to have met all inclusion criteria and none of the exclusion 
criteria, the intraprocedure record was accessed. The intraprocedure flowsheet provided 
the researcher with the anesthetic agent used, amount of dexamethasone given, amount of 
neostigmine given, intravenous fluids given, duration of anesthetic, and whether or not 
ondansetron was given intraoperatively. After the patient was deemed to have been given 
the appropriate intraoperative regimen for the study, the researcher then viewed the 
PACU flowsheet record to the PACU in and out times. The electronic medication 
administration record (EMAR) was then accessed to determine if any ondansetron or 
promethazine was given during the patient’s time in the PACU. This served as an 
indicator for the researcher for PONV in the PACU because these medications are only 
given if the patient is experiencing nausea or vomiting.  
In summary, de-identified relevant data, including patient age, gender, race, 
anesthetic agent used, intravenous fluid administered, duration of anesthetic, and the 
occurrence of early PONV in the post anesthesia care unit as evidenced by the 
administration of rescue anti-emetics ondansetron and promethazine was collected. Fifty 
patient charts were reviewed to compare dosages of dexamethasone used for each patient. 
The two samples, one consisting of patients receiving 4mg dexamethasone, and the other 
consisting of patients receiving 8mg of dexamethasone, were compared. Frequency of 
PONV in the PACU among ages 18-30, 30-40, 40-50, and 50-60 was recorded. PONV in 
the PACU amongst race and inhalation agent used were also examined. Pre-op 
medications were also recorded as well as past history of PONV and motion sickness. 
Intraoperative fluids given, amount of neostigmine, ondansetron, and dexamethasone 
administered were also recorded and analyzed.  
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The pre-existing data collected from the healthcare facility for the project 
contained protected patient health information. All information was kept confidential 
throughout the collection and analysis of data.  Patient identifiers such as the patient 
medical record numbers were not recorded. After all data was recorded and statistical 
analysis was completed, all data collection forms were shredded as requested by the IRB.  
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CHAPTER III 
ANALYSIS OF DATA 
 The goal of this capstone project was to perform a retrospective chart review to 
determine whether or not there was a significant difference between two dosages of 
dexamethasone in the prevention of PONV in the PACU. A Pearson’s chi-square test was 
used to determine whether or not there was a statistical significant difference. 
Demographic data was also collected as well as incidence of PONV among dosages of 
neostigmine and anesthetic agents used.  
Statistical Analysis 
 A Pearson’s chi-square test was completed using SPSS to make a statistical 
analysis. The chi-square test helps distinguish whether or not there is a statistically 
significant difference when comparing two different groups receiving the same 
interventions.  The chi-square test can provide the probability that the outcome and 
exposure of an event are independent (Peat, Barton, & Elliott, 2012). In this particular 
case, the fisher’s exact value was the most relevant value due to the fact that the 
incidence of PONV was less than 5 in each group. The Fisher’s exact test is generally 
used when one or more cells in a 2 x 2 table have an expected count of less than 5 (Peat, 
Barton, & Elliott, 2012). A hypothesis and null hypothesis were created for the capstone 
project. The hypothesis stated that there is a decreased incidence of early PONV in 
patients receiving 8mg of dexamethasone vs 4mg of dexamethasone. The null hypothesis 
stated that there is not a decreased incidence of early PONV in patients receiving 8mg of 
dexamethasone vs 4mg of dexamethasone. The level of significance  a probability of 
rejecting a true null hypothesis. An  value of 0.05 was used to analyze the data. 
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Results 
 The retrospective review was completed at the approved healthcare facility in the 
Southeastern United States. A convenience sample of 50 charts spanning February 2015 
to September 2015 were analyzed. Inclusion criteria included those who are female, those 
have underwent laparoscopic gynecological surgery and received dexamethasone, those 
who are non-smokers, and those who are aged 18-60 with an ASA of II or less. Exclusion 
criteria were not counted towards the chart review: those who are an ASA III or above, 
those who did not follow the recommended fasting time prior to surgery, those with a 
history of motion sickness, those with a history of PONV, those who are taking routine 
anti-emetics, those whose are deaf, those who are blind, those who are smokers, and 
those outside the age range for 18-60 years. All data was de-identified during the 
collection process and destroyed after data analysis was complete. The following tables 
summarize demographic data and findings within the sample group. Patient ages, 
ethnicity, inhalation agent used, and amount of neostigmine were all examined. 
Table 1 
Patient Age and Incidence of PONV  
 
Age 
 
PONV 4mg 
 
No PONV 4mg 
 
PONV 8mg 
 
No PONV 8mg 
 
18-29 
 
1 
 
1 
 
0 
 
1 
30-39 0 10 0 9 
40-49 1 7 3 8 
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Table 1 (continued). 
50-60 0 5 0 4 
 
Of the 50 patients examined, most of the patients fell between the age groups of 
30-49. This was anticipated before data collection began, as with most laparoscopic GYN 
procedures such as hysterectomies and tubal ligations are performed on this age group. 
Ethnicities of the recorded sample is illustrated in Table 2. 
Table 2 
Incidence of PONV among Ethnicity  
 
Ethnicity 
 
PONV 4mg 
 
No PONV 4mg 
 
PONV 8mg 
 
No PONV 8mg 
 
White 
 
1 
 
18 
 
3 
 
17 
Black 1 5 0 5 
 
Table 3 
Incidence of PONV among Inhalation Agent  
 
Inhalation Agent 
 
Sevoflurane 
 
Desflurane 
 
PONV 
 
2 
 
3 
No PONV 35 10 
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The use of sevoflurane at the capstone project data collection facility was clearly 
the inhalation agent of choice by the anesthesia providers. It is interesting to note that a 
large proportion of the patients who received desflurane experienced PONV in the 
PACU. 23% of those who received desflurane experienced PONV, while only 5.4% of 
those who received sevoflurane were positive for PONV in the PACU. The researcher 
took notice of this outlier, however, due to the small sample size of this capstone, it 
would not be a good candidate for statistical analysis of PONV among anesthetic agent 
used.  
Below, table 4 shows the amount of the paralytic reversal drug neostigmine was 
given to each patient. Neostigmine is the most commonly used paralytic reversal agent 
used, but it is believed to increase the incidence of PONV (Nagelhout & Plaus, 2014). In 
the 5 incidences of PONV, 3 received 3 mg of neostigmine, and 2 received 4 mg of 
neostigmine. It is interesting to note that the 6 patients from this sample who received 5 
mg of neostigmine, which is the maximum recommended dosage, did not experience 
PONV.  
Table 4 
Total Neostigmine Patients Received 
Neostigmine (mg) PONV No PONV 
0 0 9 
1 0 1 
2 0 4 
3 3 11 
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Table 4 (continued). 
4 2 14 
5 0 6 
 
 The data presented in table 5 below is indicative of the sample used in this study. 
There were a total of 50 subjects analyzed during this retrospective chart review, 25 
patients receiving 4mg of dexamethasone and 25 patients receiving 8mg of 
dexamethasone. The incidence of PONV in the PACU occurred almost equally across 
groups. 2 patients receiving 4mg experienced PONV while 3 patients receiving 8mg 
experienced PONV. This accounts for 8% and 12 % of the groups being analyzed 
respectively. Of all the patients measured from the population, 10% of the total 
experienced PONV in the PACU  
Table 5 
Dexamethasone PONV Cross Tabulation 
 
PONV 
Total Yes No 
Dexamethasone 4mg Count 2 23 25 
% within 
Dexamethasone 
8.0% 92.0% 100.0% 
% within PONV 40.0% 51.1% 50.0% 
% of Total 4.0% 46.0% 50.0% 
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 The Pearson’s chi-square test below, where (N=50, df=1)= .222, p=.067,  allows 
the researcher to determine whether or not there is a statistically significant difference 
between the two different dosages of dexamethasone in regards to PONV in the PACU 
among the sample. The chi-square test for association was completed. Since two of the 
cells were less than 5 due to the incidence of PONV being low, there was no statistical 
association using the Pearson Chi-Square value. Instead, the Fisher’s Exact Test was used 
in which it yielded a 1.0 on the 2 sided test and a 0.500 on the 1 sided test. These results 
yielded no statistically significant relationship among the two dosages of dexamethasone 
in the reduction of PONV.  
 
 
Table 5 (continued). 
8mg Count 3   22 25 
% within 
Dexamethasone 
12.0% 88.0% 100.0% 
% within PONV 60.0% 48.9% 50.0% 
% of Total 6.0% 44.0% 50.0% 
Total Count 5 45 50 
% within 
Dexamethasone 
10.0% 90.0% 100.0% 
% within PONV 100.0% 100.0% 100.0% 
% of Total 10.0% 90.0% 100.0% 
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Table 6 
Chi Square Tests 
 Value df 
Asymptotic 
Significance 
(two-sided) 
Exact Sig.  
(two-sided) 
Exact Sig.  
(one-sided) 
Pearson Chi-Square .222a 1 .637   
Continuity 
Correctionb 
.000 1 1.000   
Likelihood Ratio .224 1 .636   
Fisher's Exact Test    1.000 .500 
Linear-by-Linear 
Association 
.218 1 .641   
N of Valid Cases 50     
a. df=degrees of freedom. 2 cells (50.0%) have expected count less than 5. The 
minimum expected count is 2.50. 
b. Computed only for a 2x2 table 
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CHAPTER IV 
SUMMARY 
 The purpose of this capstone project was to complete a retrospective chart review 
to help determine whether or not there was a significant difference between two dosages 
of dexamethasone and the reduction of PONV in the PACU. After all data was analyzed, 
it was concluded that there was no statistically significant difference between the 
incidences of PONV in the PACU among the sample provided. It is interesting to note 
that of the 13 patients that were given desflurane, 23% experienced PONV in the PACU. 
Of the 50 patients in the sample, only ten percent experienced PONV in the PACU. As 
stated earlier, PONV affects as much as 20% to 80% of patients undergoing surgery. This 
was a relatively lower than expected total due to the fact that the women analyzed in the 
study were considered having a very high risk for PONV.  
Recommendations 
 Although the sample size was relatively small and only covered a short time 
period, it is recommended that the findings of this paper be further investigated, 
especially in terms of PONV and anesthetic agent being used. According to the clinical 
site pharmacy, dexamethasone is supplied to the clinical site in single dose 4mg vials that 
cost $2.50 per vial. While this is not a high cost for a single administration, the 
compounded cost of thousands of vials could be substantial, especially at a busy surgery 
center. One could argue that since there was no statistically significant difference 
between the two dosages of dexamethasone in this sample, that the anesthesia provider 
administer just 4mg of dexamethasone for the prevention of PONV in order to conserve 
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medication and reduce overall costs. This point can further be argued since there are 
studies reporting that 4mg of dexamethasone has been found to be just as effective in the 
reduction of PONV as 8mg. However, as all anesthesia providers know, not all cases call 
for the same medication regimens. For procedures where swelling may be a concern, 
giving 8mg of dexamethasone may be more suitable since it would aid in the reduction 
swelling and still help reduce PONV.   
Conclusion 
 In conclusion, this retrospective chart review produced no statistically significant 
difference between 4mg of dexamethasone and 8mg of dexamethasone in the reduction of 
PONV in the PACU within the sample provided. One could argue based on this sample 
that the administration of 4mg was just as efficient as 8mg in the reduction of PONV. If 
supply is low or cost is an issue, the use of 4mg dexamethasone could be used as an 
effective adjunct in anti-emetic therapy. Currently, PONV will continue to be a problem 
for patients undergoing surgery. A holistic approach in the prevention of PONV, where 
fluids are monitored, amount of neostigmine is considered, and appropriate receptors in 
the CTZ are blockaded is a good approach for anesthetist in the prevention of PONV.  
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APPENDIX A 
FORREST GENERAL HOSPITAL IRB APPROVAL LETTER
 
APPENDIX B 
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THE UNIVERSITY OF SOUTHERN MISISSIPPI IRB APPROVAL LETTER
 
APPENDIX C 
DOCTOR OF NURSING PRACTICE ESSENTIALS 
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The Essentials of Doctoral Education of Advanced Nursing Practice 
I. Scientific Underpinnings for Practice 
 The use of prescriptive theory to assess cause and effect 
relationships. The administration of dexamethasone 4mg vs 8mg in 
the prevention of PONV uses cause and effect relationships to 
draw a conclusion based on patient outcomes. The knowledge 
gained from these outcomes can be used to influence anesthesia 
practice. 
II. Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking 
 Research supports that the use of dexamethasone is effective in the 
prevention of PONV. The use of dexamethasone for prevention of 
PONV could improve patient outcomes, and quality of hospital 
stay when the patient does not suffer from symptoms of PONV. 
III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice 
 Evidence supports that dexamethasone decreases the incidence of 
PONV in women undergoing general anesthesia. Once the 
retrospective chart review is completed, data collected could 
influence current practice. 
IV. Information Systems/Technology and Patient Care Technology for the 
Improvement of Transformation of Health Care 
 The use of research databases searched during the literature review 
will provide evidence used to help determine best practice use of 
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dexamethasone for the prevention of PONV. The use of EPIC 
during the retrospective chart review will also put emphasis on 
patient care technology. 
V. Health Care Policy for Advocacy in Health Care 
 Evidence shows that dexamethasone prevents PONV in women 
undergoing general anesthesia. This information could help 
influence anesthesia providers to create facility policies involving 
the use of dexamethasone for the prevention of PONV. 
VI. Interprofessional Collaboration for Improving Patient and Population 
Health Outcomes 
 At the conclusion of the capstone projects, interprofessional 
collaboration will occur as the results are shared with local 
anesthesia providers that could be used to improve patient 
population health outcomes. 
VII. Clinical Prevention and Population Health for Improving the Nation’s 
Health 
 PONV is a common occurrence in the surgical setting, and is more 
likely to occur in women undergoing general anesthesia. 
Decreased incidence of PONV will reduce costs for the patient and 
healthcare facility providing care. The use of dexamethasone can 
help achieve this. 
VIII. Advanced Nursing Practice 
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 This capstone puts emphasis on the use of the evaluation of 
evidence-based literature to make a clinical decision for treatment 
in the prevention of PONV demonstrating advanced levels of 
clinical judgment to improve patient outcomes.  
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ASA PHYSICAL STATUS CLASSIFICATION SYSTEM 
ASA PS 
Classification 
Definition 
Examples, including, but not limited to:    
ASA I A normal healthy 
patient 
Healthy, non-smoking, no or minimal alcohol use   
ASA II A patient with 
mild systemic 
disease 
Mild diseases only without substantive functional 
limitations. Examples include (but not limited to): current 
smoker, social alcohol drinker, pregnancy, obesity (30 < BM 
< 40), well controlled DM/HTN, mild lung disease  
  
ASA III A patient with 
severe systemic 
disease 
Substantive functional limitations; One or more moderate to 
severe diseases. Examples include (but not limited to): 
poorly controlled DM or HTN, COPD, morbid obesity (BMI 
≥40), active hepatitis, alcohol dependence or abuse, 
implanted pacemaker, moderate reduction of ejection 
fraction, ESRD undergoing regularly scheduled dialysis, 
premature infant PCA < 60 weeks, history (>3 months) of 
MI, CVA, TIA, or CAD/stents.  
  
ASA IV A patient with 
severe systemic 
disease that is a 
constant threat to 
life 
Examples include (but not limited to): recent ( < 3 months) 
MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or 
severe valve dysfunction, severe reduction of ejection 
fraction, sepsis, DIC, ARD or ESRD not undergoing 
regularly scheduled dialysis 
  
ASA V A moribund 
patient who is not 
expected to 
survive without 
the operation 
Examples include (but not limited to): ruptured 
abdominal/thoracic aneurysm, massive trauma, intracranial 
bleed with mass effect, ischemic bowel in the face of 
significant cardiac pathology or multiple organ/system 
dysfunction 
  
ASA VI  A declared brain-
dead patient 
whose organs are 
being removed for 
donor purposes 
    
 
*The addition of “E” denotes Emergency surgery: (An emergency is defined as existing when delay in treatment of the patient would 
lead to a significant increase in the threat to life or body part) (American Society of Anesthesiologists, 2015) 
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DATA COLLECTION FORM 
Identification # __________ Procedure Date  
__/__/____ 
 
Age  _______ Sex  M  / F Ht.  _____   Wt.  _______ BMI ________  
Ethnicity  ______________ Smoker Y/N     ASA __________ 
Current Medications  
______________________________________________________ 
Past Medical 
History_______________________________________________________ 
 
Past Anesthesia Complications 
______________________________________________ 
Preoperative 
Medications___________________________________________________ 
Anes Start  _____________ Anes End  _____________ Total Anes  
____________ 
Surgery Start  ___________ Surgery End  
___________ 
Total Surgery  
__________ 
Intraoperative: 
ETT size_____ Inhalation agent used ______ 
Time Medication Dose 
 Ondansetron  
 Dexamethasone  
 Neostigmine  
 
IVF type:  _____________ 
EBL __________ml 
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PACU: 
 
PACU Vital Signs:  
 
BP _____  HR _____ Temp ______ 
 
PACU time in:  _________ 
Time Medication Dose 
 Ondansetron  
 Promethazine  
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